Why Novavax Could Beat Moderna in Europe After Pfizer's Huge EU Vaccine Deal
The name of the game with COVID-19 vaccines right now is supply deals. Companies with big supply agreements are in a position to make a lot of money.
Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) are arguably in the catbird's seat right now after securing a major supply deal with the European Union over the weekend. However, there could be another winner on the way as well. Novavax (NASDAQ: NVAX) just might be set to beat Moderna (NASDAQ: MRNA) in Europe now that the EU inked a major contract with Pfizer and BioNTech.
Image source: Getty Images.
Source Fool.com
